NovAccess Global (XSNX) Stock Price, News & Analysis

Company Overview

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

Key Stats

• Today's Range: $0.0004 to $0.0004
• 50-Day Range: $0.0002 to $0.01
• 52-Week Range: $0.00 to $0.05
• Volume: N/A
• Average Volume: 5,983 shs
• Market Capitalization: $17,840.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XSNX Stock Analysis - Frequently Asked Questions

How have XSNX shares performed this year?

NovAccess Global's stock was trading at $0.01 at the beginning of 2025. Since then, XSNX shares have decreased by 96.0% and is now trading at $0.0004.
View the best growth stocks for 2025 here.

How do I buy shares of NovAccess Global?

Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovAccess Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN) and Adamis Pharmaceuticals (ADMP).

Company Calendar

• Today: 1/22/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:XSNX
• CUSIP: N/A
• CIK: 1039466
• Web: www.xsunx.com
• Phone: (213) 642-9268
• Fax: 949-266-5823
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,720,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,723.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.58) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 44,600,000
• Free Float: 43,961,000
• Market Cap: $17,840.00
• Optionable: Not Optionable
• Beta: 2.19